EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Agios Pharmaceuticals EBITDA Margin % Related Terms
Agios Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Agios Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8AP vs CAPR, SNDX, SLS: EBITDA Margin % Comparison
For the Biotechnology subindustry, Agios Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agios Pharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals (FRA:8AP) has a EBITDA Margin % of -523.78% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Agios Pharmaceuticals and its competitors. According to the industry distribution chart, Agios Pharmaceuticals ranks #718 out of 945 companies in the Biotechnology industry, placing it in the top 76%.
Is Agios Pharmaceuticals' EBITDA Margin % too high?
Agios Pharmaceuticals' current EBITDA Margin % is -523.78%. Based on the distribution chart, Agios Pharmaceuticals ranks #718 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' EBITDA Margin % compare to CAPR and SNDX?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #718 out of 945 companies for EBITDA Margin %. This places Agios Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current EBITDA Margin % is -523.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (FRA:8AP) is currently considered Possible Value Trap. The stock's GF Value™ is €70.71, compared to a current price of €32.00 — trading 54.7% below its estimated fair value. The current EBITDA Margin % is -523.78%. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current EBITDA Margin % is -523.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of €32.00 is trading 54.7% below its estimated GF Value™ of €70.71.
GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:8AP:
EBITDA Margin %: -523.78%
GF Value™: €70.71 vs. price of €32.00 (54.7% below fair value)
No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score
Get the complete analysis for FRA:8AP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8AP has been successfully added to your 
